Cinal, AdnanZiemssen, FockeBartz-Schmidt, Karl U.Gelisken, Faik2025-05-102025-05-1020110721-832X1435-702X10.1007/s00417-010-1551-22-s2.0-79955577312https://doi.org/10.1007/s00417-010-1551-2https://hdl.handle.net/20.500.14720/1933Purpose To report the long-term effect of intravitreal bevacizumab on serous macular detachment (SMD) in central retinal vein occlusion (CRVO). Methods Retrospective, interventional, noncomparative case series. Nineteen consecutive patients (19 eyes) with SMD secondary to CRVO were included. Primary outcomes were the change of the best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) at final visit. Secondary outcome was the resolution of the SMD. Results The mean patient age was 65.6 years, and the mean follow-up time 21.6 months. Of the 19 eyes, 15 eyes were non-ischemic. The average number of bevacizumab injections was 5.9 from baseline to the final visit. Mean logMAR BCVA improved from 1.20 +/- 0.45 (20/317) to 0.90 +/- 0.54(20/160)P = 0.003 and mean CFT decreased from 918 +/- 280 mu m to 432 +/- 281P = 0.0001 at the final visit. The SMD resolved in 16 of the 19 eyes completely. No local or systemic complication was observed. Conclusion In this retrospective case series, a significant improvement of the vision and resolution of the SMD was found after bevacizumab treatment for CRVO with SMD. Large case series are necessary to evaluate the role of the intravitreal bevacizumab treatment for CRVO associated with SMD.eninfo:eu-repo/semantics/closedAccessAnti VegfBevacizumabRetinal Vein OcclusionMacular Serous DetachmentTreatmentVascular Endothelial Growth FactorArticle2494Q2Q351352021053008WOS:000290034700007